Akèy › Kansè nan tete › Colorado
Etid klinik pou Kansè nan tete nan Colorado
53 etid pou Kansè nan tete ap chèche patisipan nan sit nan Colorado.
Vil nan Colorado
- Denver28 etid
- Aurora27 etid
- Highlands Ranch12 etid
- Centennial9 etid
- Grand Junction7 etid
- Loveland7 etid
- Greeley7 etid
- Colorado Springs7 etid
- Fort Collins6 etid
- Lakewood5 etid
- Longmont5 etid
- Boulder4 etid
- Westminster4 etid
- Pueblo4 etid
- Thornton3 etid
- Arvada3 etid
Tèks ofisyèl etid la (Anglè)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Rocky Mountain Cancer Center, Denver
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Rocky Mountain Cancer Centers, Denver
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Rocky Mountain Regional VA Medical Center, Aurora
- UCHealth University of Colorado Hospital, Aurora
- Penrose-Saint Francis Healthcare, Colorado Springs
- ak 15 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- University of Colorado Denver - School of Medicine - Anschutz Medical Campus, Aurora
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07701941A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Rocky Mountain Cancer Centers, Denver
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07102381A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- University of Colorado School of Medicine, Aurora
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06369285BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Sarah Cannon Research Institute (Scri) At Health One, Denver
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06120283A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 0021), Grand Junction
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07060807A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Intermountain Health Cancer Center Saint Joseph ( Site 0062), Denver
- Rocky Mountain Cancer Centers (RMCC) ( Site 8006), Denver
- Intermountain Health St. Mary's Regional Hospital ( Site 0054), Grand Junction
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- University of Colorado Anschutz Medical Campus ( Site 0061), Aurora
- UCHealth Cherry Creek Medical Center ( Site 0094), Denver
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312176The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- University of Colorado Anschutz Medical Campus, Aurora
- UCHealth Cherry Creek Medical Center, Denver
- UCHealth Highlands Ranch Hospital, Highlands Ranch
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06377852A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Aurora
- Research Site, Denver
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Saint Joseph Hospital - Cancer Centers of Colorado, Denver
- Lutheran Hospital - Cancer Centers of Colorado, Golden
- Saint Mary's Regional Hospital - Cancer Centers of Colorado, Grand Junction
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07007559Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Aurora
- Clinical Trial Site, Denver
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Intermountain Health, Grand Junction
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- UCHealth Harmony, Fort Collins
- Cancer Centers of Colorado St. Mary's Regional Hospital, Grand Junction
- Banner MD Anderson Cancer Center at North Colorado Medical Center, Greeley
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Banner MD Anderson Cancer Center at North Colorado Medical Center, Greeley
- Banner MD Anderson Cancer Center at McKee Medical Center, Loveland
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07287098A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- St. Joseph Hospital-Cancer Centers of Colorado, Denver
- Rocky Mountain Cancer Centers, LLP, Lone Tree
- AHMG Hematology and Oncology, Parker
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616A Phase 1/1b Study of IAM1363 in HER2 Cancers
- University of Colorado Cancer Center, Aurora
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
- Outpatient CTRC, Aurora
- University of Colorado Cancer Center, Aurora
Ap rekriteFaz 1
Laj 21 ak plis · Fanm · Mizajou Sep 4, 2026 · NCT06430541Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Skin Cancer Institute, Englewood
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07287917Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Rocky Mountain Cancer Centers, LLP, Longmont
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06982521The Vanguard Study: Testing a New Way to Screen for Cancer
- Keefe Memorial Hospital, Cheyenne Wells
- Kaiser Permanente-Franklin, Denver
- Poudre Valley Hospital, Fort Collins
- ak 5 plis
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
- Banner MD Anderson Northern Colorado, Loveland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07076485Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- UCHealth University of Colorado Hospital, Aurora
- Penrose-Saint Francis Healthcare, Colorado Springs
- Rocky Mountain Cancer Centers-Penrose, Colorado Springs
- ak 18 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute at HealthONE, Denver
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07029399Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Sarah Cannon Research Institute - Denver DDU, Denver
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06582017A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute (SCRI) at HealthONE-Denver, Denver
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07383506A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- University Of Colorado Hospital - Anschutz Cancer Pavilion, Aurora
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06764940A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Local Institution - 0289, Aurora
- Rocky Mountain Cancer Centers, Denver
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06926868Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Rocky Mountain Cancer Centers, Denver
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Aug 6, 2026 · NCT05232916E-Mindfulness Approaches for Living After Breast Cancer
- UCHealth University of Colorado Hospital, Aurora
- UCHealth Memorial Hospital Central, Colorado Springs
- Memorial Hospital North, Colorado Springs
Ap rekriteFaz 3
Laj 18 a 50 · Tout sèks · Mizajou Aug 4, 2026 · NCT06748222A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Rocky Mountain Cancer Center, Littleton
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT06695845First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- University of Colorado Cancer Center, Aurora
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT05768139Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
- Rocky Mountain Cancer Centers, Lone Tree
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT07558733Integrated Cancer Repository for Cancer Research
- Advent Health, Greenwood Village
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- University of Colorado Anschutz Medical Campus ( Site 0057), Aurora
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 22, 2026 · NCT06686394A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Rocky Mountain Cancer Centers LLP, Aurora
- Rocky Mountain Cancer Centers LLP, Boulder
- Rocky Mountain Cancer Centers LLP, Centennial
- ak 10 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT07062965Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Denver
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT06239194I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Colorado Cancer Center, Aurora
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT01042379Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.